TY - JOUR
T1 - A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets
AU - Taguchi, Ayumu
AU - Taylor, Allen D.
AU - Rodriguez, Jaime
AU - Çeliktaş, Müge
AU - Liu, Hui
AU - Ma, Xiaotu
AU - Zhang, Qing
AU - Wong, Chee Hong
AU - Chin, Alice
AU - Girard, Luc
AU - Behrens, Carmen
AU - Lam, Wan L.
AU - Lam, Stephen
AU - Minna, John D.
AU - Wistuba, Ignacio I.
AU - Gazdar, Adi F.
AU - Hanash, Samir M.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the expression of particular antigens is limited to a subset of tumors of a given type. Thus, there is a need to identify antigens with complementary expression patterns for effective therapeutic intervention. In this study, we searched for genes that were distinctly expressed at a higher level in lung tumor tissue and the testes compared with other nontumor tissues and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member of the VCX/Y gene family, was expressed at the protein level in approximately 20% of lung adenocarcinomas and 35% of squamous cell carcinomas, but not expressed in normal lung tissues. Among CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors. The CT antigen VCX/Y gene family broadens the spectrum of CT antigens expressed in lung adenocarcinomas for clinical applications.
AB - Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the expression of particular antigens is limited to a subset of tumors of a given type. Thus, there is a need to identify antigens with complementary expression patterns for effective therapeutic intervention. In this study, we searched for genes that were distinctly expressed at a higher level in lung tumor tissue and the testes compared with other nontumor tissues and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member of the VCX/Y gene family, was expressed at the protein level in approximately 20% of lung adenocarcinomas and 35% of squamous cell carcinomas, but not expressed in normal lung tissues. Among CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors. The CT antigen VCX/Y gene family broadens the spectrum of CT antigens expressed in lung adenocarcinomas for clinical applications.
UR - http://www.scopus.com/inward/record.url?scp=84907042717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907042717&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-13-3725
DO - 10.1158/0008-5472.CAN-13-3725
M3 - Article
C2 - 24970476
AN - SCOPUS:84907042717
VL - 74
SP - 4694
EP - 4705
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 17
ER -